瑞普利单抗-话题@MedSci

#瑞普利单抗#

46篇内容 | 1847人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2027455, encodeId=e64e202e4550e, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=君实生物特瑞普利单抗治疗鼻咽癌再获欧盟孤儿药资格认定, objectType=article, longId=737113, objectId=f35ee3711364, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f35ee3711364, replyNumber=0, likeNumber=97, createdTime=2022-12-18, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f35ee3711364, moduleTitle=君实生物特瑞普利单抗治疗鼻咽癌再获欧盟孤儿药资格认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f35ee3711364)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027453, encodeId=ada1202e4537e, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=君实生物宣布icatolimab和特瑞普利单抗近40项研究成果在2022年美国临床肿瘤学会（ASCO）年会上公布, objectType=article, longId=728850, objectId=e55ee2885022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e55ee2885022, replyNumber=0, likeNumber=81, createdTime=2022-09-20, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e55ee2885022, moduleTitle=君实生物宣布icatolimab和特瑞普利单抗近40项研究成果在2022年美国临床肿瘤学会（ASCO）年会上公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e55ee2885022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027452, encodeId=eeb9202e452e0, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=君实生物特瑞普利单抗联合化疗一线治疗食管鳞癌获得国家药品监督管理局批准, objectType=article, longId=727117, objectId=8db3e271176b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8db3e271176b, replyNumber=0, likeNumber=138, createdTime=2023-03-26, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8db3e271176b, moduleTitle=君实生物特瑞普利单抗联合化疗一线治疗食管鳞癌获得国家药品监督管理局批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8db3e271176b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027449, encodeId=034e202e44926, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, objectType=article, longId=299451, objectId=fc31299451e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31299451e9, replyNumber=0, likeNumber=119, createdTime=2022-04-14, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31299451e9, moduleTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31299451e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027441, encodeId=a158202e441c9, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=CCR：君实特瑞普利单抗对尿路上皮癌具有持久的临床应答（POLARIS-03研究）, objectType=article, longId=220472, objectId=39872204e2fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39872204e2fd, replyNumber=0, likeNumber=88, createdTime=2022-09-10, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39872204e2fd, moduleTitle=CCR：君实特瑞普利单抗对尿路上皮癌具有持久的临床应答（POLARIS-03研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39872204e2fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027437, encodeId=670f202e437aa, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=Nat Med：特瑞普利单抗联合化疗一线治疗晚期鼻咽癌，效果惊艳（JUPITER-02研究）, objectType=article, longId=217410, objectId=6f0f21e41074, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f0f21e41074, replyNumber=0, likeNumber=82, createdTime=2021-09-25, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f0f21e41074, moduleTitle=Nat Med：特瑞普利单抗联合化疗一线治疗晚期鼻咽癌，效果惊艳（JUPITER-02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f0f21e41074)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027450, encodeId=727d202e4509c, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=J Immunother Cancer：Toripalimab（特瑞普利单抗）联合axitinib（阿昔替尼）治疗转移性粘膜黑色素瘤的3年生存更新结果, objectType=article, longId=299734, objectId=92ab299e343d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92ab299e343d, replyNumber=0, likeNumber=112, createdTime=2023-01-04, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92ab299e343d, moduleTitle=J Immunother Cancer：Toripalimab（特瑞普利单抗）联合axitinib（阿昔替尼）治疗转移性粘膜黑色素瘤的3年生存更新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92ab299e343d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027442, encodeId=aa14202e442c2, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=J Immunother Cancer：特瑞普利单抗（Toripalimab）联合IMRT治疗复发鼻咽癌（rNPC）的疗效和安全性, objectType=article, longId=220654, objectId=94b8220654c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94b8220654c0, replyNumber=0, likeNumber=89, createdTime=2021-12-25, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94b8220654c0, moduleTitle=J Immunother Cancer：特瑞普利单抗（Toripalimab）联合IMRT治疗复发鼻咽癌（rNPC）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94b8220654c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027451, encodeId=8a7c202e451c9, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=君实生物特瑞普利单抗治疗小细胞肺癌获得美国FDA孤儿药资格认定, objectType=article, longId=724273, objectId=0e42e24273f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e42e24273f5, replyNumber=0, likeNumber=102, createdTime=2022-10-13, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e42e24273f5, moduleTitle=君实生物特瑞普利单抗治疗小细胞肺癌获得美国FDA孤儿药资格认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e42e24273f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027439, encodeId=2a64202e4396e, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=君实生物特瑞普利单抗治疗尿路上皮癌POLARIS-03研究获《临床癌症研究》杂志在线发表, objectType=article, longId=220465, objectId=a903220465fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a903220465fc, replyNumber=0, likeNumber=51, createdTime=2022-01-07, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a903220465fc, moduleTitle=君实生物特瑞普利单抗治疗尿路上皮癌POLARIS-03研究获《临床癌症研究》杂志在线发表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a903220465fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027454, encodeId=5e94202e45499, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=美国FDA受理君实生物重新提交的特瑞普利单抗治疗鼻咽癌上市申请, objectType=article, longId=731534, objectId=ae54e315347b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae54e315347b, replyNumber=0, likeNumber=91, createdTime=2023-02-14, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae54e315347b, moduleTitle=美国FDA受理君实生物重新提交的特瑞普利单抗治疗鼻咽癌上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae54e315347b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027444, encodeId=42b8202e444f4, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=君实生物特瑞普利单抗新增两项适应症纳入国家医保目录, objectType=article, longId=221523, objectId=b747221523b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b747221523b7, replyNumber=0, likeNumber=77, createdTime=2022-11-17, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b747221523b7, moduleTitle=君实生物特瑞普利单抗新增两项适应症纳入国家医保目录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b747221523b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027431, encodeId=4747202e431f3, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=ASCO 2021：中国之声！特瑞普利单抗一线治疗复发/转移性鼻咽癌研究取得突破性进展，有望改写国际新标准！, objectType=article, longId=212418, objectId=8c9f212418e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c9f212418e1, replyNumber=0, likeNumber=143, createdTime=2022-01-17, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c9f212418e1, moduleTitle=ASCO 2021：中国之声！特瑞普利单抗一线治疗复发/转移性鼻咽癌研究取得突破性进展，有望改写国际新标准！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c9f212418e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027440, encodeId=b053202e44085, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=君实生物特瑞普利单抗治疗食管癌获得美国FDA孤儿药资格认定, objectType=article, longId=220466, objectId=682f220466e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=682f220466e5, replyNumber=0, likeNumber=89, createdTime=2021-12-26, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=682f220466e5, moduleTitle=君实生物特瑞普利单抗治疗食管癌获得美国FDA孤儿药资格认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=682f220466e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027447, encodeId=c0cb202e447b4, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, objectType=article, longId=293109, objectId=d234293109ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d234293109ad, replyNumber=0, likeNumber=94, createdTime=2022-02-27, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d234293109ad, moduleTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d234293109ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027434, encodeId=c09a202e434d6, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=君实生物在世界肺癌大会（WCLC）首次发布特瑞普利单抗一线治疗非小细胞肺癌三期研究数据, objectType=article, longId=217082, objectId=044321e0828e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=044321e0828e, replyNumber=0, likeNumber=91, createdTime=2022-06-18, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=044321e0828e, moduleTitle=君实生物在世界肺癌大会（WCLC）首次发布特瑞普利单抗一线治疗非小细胞肺癌三期研究数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=044321e0828e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027438, encodeId=7b76202e438d2, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=美国FDA受理君实生物特瑞普利单抗治疗鼻咽癌的上市申请, objectType=article, longId=220463, objectId=b25022046347, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b25022046347, replyNumber=0, likeNumber=133, createdTime=2022-09-12, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b25022046347, moduleTitle=美国FDA受理君实生物特瑞普利单抗治疗鼻咽癌的上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b25022046347)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027445, encodeId=ef18202e4450b, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理, objectType=article, longId=259943, objectId=cceb25994367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cceb25994367, replyNumber=0, likeNumber=82, createdTime=2022-06-23, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cceb25994367, moduleTitle=君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cceb25994367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027446, encodeId=ebf5202e446d0, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后, objectType=article, longId=293055, objectId=28ee293055ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28ee293055ec, replyNumber=0, likeNumber=99, createdTime=2022-07-22, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28ee293055ec, moduleTitle=Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28ee293055ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027448, encodeId=4e79202e448b9, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, objectTitle=君实生物特瑞普利单抗联合化疗作为术后辅助治疗胃癌III期临床研究完成首例患者给药, objectType=article, longId=295432, objectId=53a8295432d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53a8295432d2, replyNumber=0, likeNumber=117, createdTime=2023-01-21, rootId=0, userName=lfcmxl, userId=da20314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53a8295432d2, moduleTitle=君实生物特瑞普利单抗联合化疗作为术后辅助治疗胃癌III期临床研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53a8295432d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

瑞普利单抗

2020-05-29

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

君实生物特瑞普利单抗治疗鼻咽癌再获欧盟孤儿药资格认定

2022-12-18

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

君实生物宣布icatolimab和特瑞普利单抗近40项研究成果在2022年美国临床肿瘤学会（ASCO）年会上公布

2022-09-20

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

君实生物特瑞普利单抗联合化疗一线治疗食管鳞癌获得国家药品监督管理局批准

2023-03-26

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效

2022-04-14

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

CCR：君实特瑞普利单抗对尿路上皮癌具有持久的临床应答（POLARIS-03研究）

2022-09-10

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

Nat Med：特瑞普利单抗联合化疗一线治疗晚期鼻咽癌，效果惊艳（JUPITER-02研究）

2021-09-25

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

J Immunother Cancer：Toripalimab（特瑞普利单抗）联合axitinib（阿昔替尼）治疗转移性粘膜黑色素瘤的3年生存更新结果

2023-01-04

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

J Immunother Cancer：特瑞普利单抗（Toripalimab）联合IMRT治疗复发鼻咽癌（rNPC）的疗效和安全性

2021-12-25

医者仁心 (审核中...)

前往app查看评论内容

#瑞普利单抗#

君实生物特瑞普利单抗治疗小细胞肺癌获得美国FDA孤儿药资格认定

2022-10-13

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

君实生物特瑞普利单抗治疗尿路上皮癌POLARIS-03研究获《临床癌症研究》杂志在线发表

2022-01-07

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

美国FDA受理君实生物重新提交的特瑞普利单抗治疗鼻咽癌上市申请

2023-02-14

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

君实生物特瑞普利单抗新增两项适应症纳入国家医保目录

2022-11-17

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

ASCO 2021：中国之声！特瑞普利单抗一线治疗复发/转移性鼻咽癌研究取得突破性进展，有望改写国际新标准！

2022-01-17

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

君实生物特瑞普利单抗治疗食管癌获得美国FDA孤儿药资格认定

2021-12-26

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性

2022-02-27

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

君实生物在世界肺癌大会（WCLC）首次发布特瑞普利单抗一线治疗非小细胞肺癌三期研究数据

2022-06-18

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

美国FDA受理君实生物特瑞普利单抗治疗鼻咽癌的上市申请

2022-09-12

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理

2022-06-23

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后

2022-07-22

lfcmxl (审核中...)

前往app查看评论内容

#瑞普利单抗#

君实生物特瑞普利单抗联合化疗作为术后辅助治疗胃癌III期临床研究完成首例患者给药

2023-01-21

科室
- - 订阅+
  - 更多科室
工具
服务